Facilitating and restraining virus infection using cell-attachable soluble viral receptors.
ACE2
SARS-CoV-2
antibodies
cell entry
cell fusion
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
05 Nov 2024
05 Nov 2024
Historique:
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
31
10
2024
Statut:
ppublish
Résumé
SARS-CoV-2 uses the receptor binding domain (RBD) of its spike protein to recognize and infect host cells by binding to the cell surface receptor angiotensin converting enzyme 2 (ACE2). The ACE2 receptor is composed of peptidase domain (PD), collectrin-like domain, transmembrane domain, and short cytoplasmic domain, and may exist as a dimer on cell surface. The RBD binding site is located atop of the ACE2 PD, but the involvement of other domains in virus infection is uncertain. We found that the ACE2 PD alone, whether anchored to cell membrane via a glycosylphosphatidylinositol anchor or attached to another surface protein, is fully functional as a receptor for spike-mediated cell fusion and virus infection. However, for ACE2 to function as the viral receptor, the RBD binding site must be positioned in close proximity to the cell membrane. Elevating the surface height of ACE2 using long and rigid protein spacers reduces or eliminates cell fusion and virus infection. Moreover, we found that the RBD-targeting neutralizing antibodies, nanobodies, and de novo designed miniprotein binders, when present on cell surface, also act as viral receptors, facilitating cell fusion and virus infection. Our data demonstrate that RBD binding and close membrane proximity are essential properties for a receptor to effectively mediate SARS-CoV-2 infection. Importantly, we show that soluble RBD-binders can be engineered to make cells either susceptible or resistant to virus infection, which has significant implications for antiviral therapy and various virus-mediated applications.
Identifiants
pubmed: 39480852
doi: 10.1073/pnas.2414583121
doi:
Substances chimiques
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Spike Glycoprotein, Coronavirus
0
Receptors, Virus
0
spike protein, SARS-CoV-2
0
ACE2 protein, human
EC 3.4.17.23
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2414583121Subventions
Organisme : HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
ID : R01HL131836
Organisme : HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
ID : R01HL175474
Organisme : HHS | NIH | National Institute of General Medical Sciences (NIGMS)
ID : R01GM137143
Déclaration de conflit d'intérêts
Competing interests statement:J.Z., H.Z., H.T.T.N., and Z.W. have two provisional patent applications that incorporate discoveries described in this manuscript. One is related to the design of longer version of soluble viral receptors or antibodies as antiviral agents. The other is a method of using soluble viral receptors to introduce cell susceptibility for virus infection and membrane fusion.